Vigorous inflammatory responses in noninfectious pulmonary complication induced by donor lymphocyte infusion

Nishie, Miyuki; Fujii, Nobuharu; Mimura, Yusuke; Asano, Takeru; Mimura‐Kimura, Yuka; Aoe, Keisuke; M, Aoe; Nakashima, Hiromi; Fujiwara, Hideaki; Nishimori, Hisakazu; Matsuoka, Ken; Kondo, Eisei; Maeda, Yoshinobu; Tanimoto, Mitsune

doi:10.1111/trf.13283

Cited by 2 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, a GVL effect of DLI in post-transplantation relapse has been observed. The use of DLIs is not without risk, however, with case reports of unusual side effects, including polymyositis, autoimmune manifestations, and noninfectious pulmonary toxicity [79,80]. The Blood and Marrow Transplant Clinical Trials Network has recognized a composite endpoint for future transplantation clinical trials of GVHD-free, relapse-free survival.…”

Section: DLImentioning

confidence: 99%

Cellular Immunotherapy for Hematologic Malignancies: Beyond Bone Marrow Transplantation

Cirillo

Tan

Sturm

et al. 2018

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

Immunotherapy has changed treatment practices for many hematologic malignancies. Even in the current era of targeted therapy, chemotherapy remains the backbone of treatment for many hematologic malignancies, especially in acute leukemias, where relapse remains the major cause of mortality. Application of novel immunotherapies in hematology attempts to harness the killing power of the immune system against leukemia and lymphoma. Cellular immunotherapy is evolving rapidly for high-risk hematologic disorders. Recent advances include chimeric antigen-receptor T cells, mesenchymal stromal/stem cells, dendritic cell tumor vaccines, cytokine-induced killer cells, and virus-specific T cells. The advantages of nontransplantation cellular immunotherapy include suitability for patients for whom transplantation has failed or is contraindicated, and a potentially less-toxic treatment alternative to transplantation for relapsed/refractory patients. This review examines those emerging cellular immunotherapies that are changing treatment paradigms for patients with hematologic malignancies.

show abstract

Section: DLImentioning

confidence: 99%

Cellular Immunotherapy for Hematologic Malignancies: Beyond Bone Marrow Transplantation

Cirillo

Tan

Sturm

et al. 2018

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

show abstract

“…DLI represents a potential aggression factor, leading to a cytokine storm. NISHIE et al [7] recently reported a significant elevation of pro-inflammatory cytokines and chemokines in serum after lymphocyte reinfusion. Allo-HSCT patients are frequently infected or colonised by virus in respiratory samples, especially herpesvirus and adenovirus.…”

mentioning

confidence: 97%

Fatal acute respiratory distress syndrome with diffuse alveolar damage: donor lymphocyte infusion imputability?

et al. 2016

View full text Add to dashboard Cite

show abstract

Vigorous inflammatory responses in noninfectious pulmonary complication induced by donor lymphocyte infusion

Abstract: Inflammatory effectors by recipient cells, rather than allogeneic responses by donor cells, played an important role in the pathogenesis of NIPCs after DLI in the present case.

Cited by 2 publications

References 22 publications

Cellular Immunotherapy for Hematologic Malignancies: Beyond Bone Marrow Transplantation

Cellular Immunotherapy for Hematologic Malignancies: Beyond Bone Marrow Transplantation

Fatal acute respiratory distress syndrome with diffuse alveolar damage: donor lymphocyte infusion imputability?

Contact Info

Product

Resources

About